Active Biotech AB to Present at the JP Morgan 30th Annual Healthcare Conference

LUND, SWEDEN--(Marketwire - January 04, 2012) - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the JP Morgan 30(th) Annual Healthcare Conference held January 8-12, 2012 in San Francisco, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include the laquinimod MS project, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the Phase III prostate cancer project TASQ in co-development with Ipsen, as well as ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com.

The presentation will take place on January 12, at 8:00 am PST (Pacific Standard Time) / 17.00 Central European Time.

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for Systemic Sclerosis as well as RhuDex™ for RA. Please visit www.activebiotech.com for more information.


Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on January 4, 2012.

Active Biotech to Present at JP Morgan:

http://hugin.info/1002/R/1574671/490249.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

[HUG#1574671]


Contacts:
Active Biotech AB
Hans Kolam, CFO
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Back to news